UK markets closed
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • FTSE 250

    20,961.31
    -334.92 (-1.57%)
     
  • AIM

    1,163.26
    -10.13 (-0.86%)
     
  • GBP/EUR

    1.1617
    +0.0020 (+0.17%)
     
  • GBP/USD

    1.3827
    -0.0067 (-0.48%)
     
  • BTC-GBP

    34,951.86
    +868.84 (+2.55%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • DOW

    31,496.30
    +572.16 (+1.85%)
     
  • CRUDE OIL

    66.28
    +2.45 (+3.84%)
     
  • GOLD FUTURES

    1,698.20
    -2.50 (-0.15%)
     
  • NIKKEI 225

    28,864.32
    -65.78 (-0.23%)
     
  • HANG SENG

    29,098.29
    -138.50 (-0.47%)
     
  • DAX

    13,920.69
    -135.65 (-0.97%)
     
  • CAC 40

    5,782.65
    -48.00 (-0.82%)
     

Worldwide Self-Monitoring Blood Glucose Devices Industry to 2027 - Opportunity Analysis and Forecasts

Research and Markets
·7-min read

Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Global Self-Monitoring Blood Glucose Devices Market by Product, Application, and End User: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global self-monitoring blood glucose devices market was valued at $8,490. 79 million in 2019, and is projected to reach $11,991. 98 million by 2027, growing at a CAGR of 4. 2% from 2020 to 2027. Diabetes is a clinical condition where a person has an elevated blood glucose level caused due to inefficiency of pancreases to produce insulin. Glucose monitoring is one of the essential steps towards diabetes management by testing the glucose levels in blood.

Monitoring of blood glucose provides important data for patients to make daily management decisions such as food intake, insulin dose, and physical exercise. Self-monitoring blood glucose (SMBG) is a modern diabetes management procedure, which involves usage of blood glucose meters by patients to check their glucose levels quickly and provide an accurate measure of capillary glucose concentration. SMBG technology uses test strips, lancets, and blood glucose meters to achieve long-term glycemic control.

Factors such as increase in incidence rate of diabetes and The rise in risk factors that lead to diabetes are the key factors driving the growth of the global self-monitoring blood glucose devices market. Moreover, technological advancements in the field of diabetes monitoring devices and The rise in geriatric population boost the market growth. However, blood glucose monitoring devices do not measure the exact level of glucose in blood and can give inaccurate results, which hamper the market growth. Conversely, high growth potential in untapped markets and The rise in awareness about diabetes monitoring devices are expected to provide lucrative opportunities for the expansion of the global market in the near future.

The self-monitoring blood glucose devices market is segmented into product, application, end user, and region. Depending on product, the market is divided into test strips, lancets, and blood glucose meters. The applications covered in the study include 1 diabetes, type 2 diabetes, and gestational diabetes. On the basis of end user, the market is fragmented into hospitals, home settings, and diagnostic centers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The report provides extensive competitive analysis and profiles of key market players such as Abbott Laboratories, Bionime Corporation, B. Braun Melsungen AG, F. Hoffmann-La Roche Ltd., LifeScan IP Holdings, LLC, PHC Holdings Corporation, Terumo Corporation, Trividia Health, Inc. (Sinocare Inc. ), ARKRAY, Inc., and Ypsomed Holding AG.

Key Benefits

  • This report entails a detailed quantitative analysis of the current market trends from 2019 to 2027 to identify the prevailing opportunities.

  • Self-monitoring blood glucose devices market size and market estimations are based on comprehensive analysis of the key developments in the industry.

  • In-depth analysis based on region assists to understand the regional market and the strategic business planning.

  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Key Topics Covered:

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled in the Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models

Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. Cxo Perspective

Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Market Share Analysis, 2019 (%)
3.4. Porter'S Five Forces Analysis
3.4.1. Moderate Bargaining Power of Buyers
3.4.2. High Bargaining Power of Suppliers
3.4.3. Low Threat of Substitution
3.4.4. Moderate Threat of New Entrant
3.4.5. High Competitive Rivalry
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Increase in the Incidence Rate of Diabetes
3.5.1.2. The Rise in Geriatric Population
3.5.1.3. Technological Advancements in Diabetes Monitoring Devices
3.5.1.4. The Rise in Risk Factors That Lead to Diabetes
3.5.2. Restraints
3.5.2.1. Inaccurate Results
3.5.3. Opportunity
3.5.3.1. Increase in Awareness for Diabetes Monitoring Devices
3.5.3.2. Untapped Market Opportunities in the Developing Regions
3.5.4. Impact Analyses
3.6. Impact Analysis of Covid-19 on Self-Monitoring Blood Glucose Devices Market

Chapter 4: Self-Monitoring Blood Glucose Devices Market, by Product
4.1. Overview
4.1.1. Market Size and Forecast, by Product
4.1.2. Market Size and Forecast, by Product (Million Units)
4.2. Test Strips
4.2.1. Key Market Trends, Growth Factors, and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Analysis, by Country
4.3. Lancets
4.3.1. Key Market Trends, Growth Factors, and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Analysis, by Country
4.4. Blood Glucose Meters
4.4.1. Key Market Trends, Growth Factors, and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Analysis, by Country

Chapter 5: Self-Monitoring Blood Glucose Devices Market, by Application
5.1. Overview
5.1.1. Market Size and Forecast, by Revenue
5.2. Type 1 Diabetes
5.2.1. Market Size and Forecast, by Region
5.2.2. Market Analysis, by Country
5.3. Type 2 Diabetes
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Analysis, by Country
5.4. Gestational Diabetes
5.4.1. Market Size and Forecast, by Region
5.4.2. Market Analysis, by Country

Chapter 6: Self-Monitoring Blood Glucose Devices Market, by End-user
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Hospitals
6.2.1. Market Size and Forecast, by Region
6.2.2. Market Analysis, by Country
6.3. Home Settings
6.3.1. Market Size and Forecast, by Region
6.3.2. Market Analysis, by Country
6.4. Diagnostic Centers
6.4.1. Market Size and Forecast, by Region
6.4.2. Market Analysis, by Country

Chapter 7: Self-Monitoring Blood Glucose Devices Market, by Region
7.1. Overview
7.2. North America
7.3. Europe
7.4. Asia-Pacific
7.5. LAMEA

Chapter 8: Company Profiles
8.1. Abbott Laboratories
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves and Developments
8.2. Arkray, Inc.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Product Portfolio
8.2.4. Key Strategic Moves and Developments
8.3. B. Braun Melsungen AG
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.3.6. Key Strategic Moves and Developments
8.4. Bionime Corporation
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Product Portfolio
8.5. F. Hoffmann-La Roche Ltd.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves and Developments
8.6. Lifescan Ip Holdings, LLC (Platinum Equity)
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Product Portfolio
8.6.4. Key Strategic Moves and Developments
8.7. Phc Holdings Corporation
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.8. Terumo Corporation
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.9. Trividia Health, Inc. (Sinocare)
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.10. Ypsomed Holding AG
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves and Developments

For more information about this report visit https://www.researchandmarkets.com/r/ezjn91

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900